OCT4 mutations in human erythroleukemic cells: implications for multiple drug resistance (MDR) phenotype

Molecular and Cellular Biochemistry

Volumn 400, Issue 1-2, 2015, Pages 41-50

  Oliveira, Bruno Rodrigues ^a   Figueiredo, Marcio Azevedo ^a   Trindade, Gilma Santos ^a   Marins, Luis Fernando ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE   (Brazil)

Author keywords

ABC transporters; Gene expression; K562; K562 Lucena; Phosphorylation motifs; Transcription factors

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 1; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOX3; TRANSCRIPTION FACTOR FOXD3; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; VINCRISTINE; POU5F1 PROTEIN, HUMAN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BINDING SITE; CANCER RESISTANCE; CONTROLLED STUDY; DNA BINDING; ERYTHROLEUKEMIA; ERYTHROLEUKEMIA CELL; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; K562 CELL LINE; MULTIDRUG RESISTANCE; PHENOTYPE; PROMOTER REGION; PROTEIN PHOSPHORYLATION; CANCER STEM CELL; GENETICS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MUTATION; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MUTATION; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PHOSPHORYLATION;

EID: 84922004408     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-014-2260-7     Document Type: Article

References (38)

1. Alison MR, Lim SM, Nicholson LJ (2011) Cancer stem cells: problems for therapy? J Pathol 223(2):147–161
2. Hu T, Liu S, Breiter DR, Wang F, Tang Y, Sun S (2008) Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res 68(16):6533–6540
3. Klonisch T, Wiechec E, Hombach-Klonisch S, Ande SR, Wesselborg S, Schulze-Osthoff K et al (2008) Cancer stem cell markers in common cancers—therapeutic implications. Trends Mol Med 14(10):450–460
4. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730–737
5. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L et al (2009) Highly tumorigenic lung cancer CD133 + cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106(38):16281–16286
6. Nguyen LV, Vanner R, Dirks P, Eaves CJ (2012) Cancer stem cells: an evolving concept. Nat Rev Cancer 12(2):133–143
7. Dalerba P, Cho RW, Clarke MF (2007) Cancer stem cells: models and concepts. Annu Rev Med 58:267–284
8. Hammachi F, Morrison GM, Sharov AA, Livigni A, Narayan S, Papapetrou EP et al (2012) Transcriptional activation by Oct4 is sufficient for the maintenance and induction of pluripotency. Cell Rep 1(2):99–109
9. Wei F, Schöler HR, Atchison ML (2007) Sumoylation of Oct4 enhances its stability, DNA binding, and transactivation. J Biol Chem 282(29):21551–21560
10. Walker E, Ohishi M, Davey RE, Zhang W, Cassar PA, Tanaka TS et al (2007) Prediction and testing of novel transcriptional networks regulating embryonic stem cell self-renewal and commitment. Cell Stem Cell 1(1):71–86
11. Liu Y, Labosky PA (2008) Regulation of embryonic stem cell self-renewal and pluripotency by Foxd3. Stem Cells 26(10):2475–2484
12. Saxe JP, Tomilin A, Schöler HR, Plath K, Huang J (2009) Post-translational regulation of Oct4 transcriptional activity. PLoS ONE 4(2):e4467
13. Wang X, Dai J (2010) Concise review: isoforms of OCT4 contribute to the confusing diversity in stem cell biology. Stem Cells 28(5):885–893
14. Zhang W, Wang X, Xiao Z, Liu W, Chen B, Dai J (2010) Mapping of the minimal internal ribosome entry site element in the human embryonic stem cell gene OCT4B mRNA. Biochem Biophys Res Commun 394(3):750–754
15. Lim HY, Do HJ, Lee WY, Kim DK, Seo HG, Chung HJ et al (2009) Implication of human OCT4 transactivation domains for self-regulatory transcription. Biochem Biophys Res Commun 385(2):148–153
16. Fang XF, Zhang WY, Zhao N, Yu W, Ding D, Hong X et al (2011) Genome-wide analysis of OCT4 binding sites in glioblastoma cancer cells. J Zhejiang Univ Sci B 12(10):812–819
17. Looijenga LHJ, Stoop H, Leeuw HPJCD, Tumors C, Roozendaal KEPV, Zoelen EJJV et al (2003) POU5F1 (OCT3/4) Identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 63:2244–2250
18. Linn DE, Yang X, Sun F, Xie Y, Xen H, Jiang R et al (2010) A role for OCT4 in tumor initiation of drug-resistance prostate cancer cells. Genes Cancer 1(9):908–916
19. Wang XQ, Ongkeko WM, Chen L, Yang ZF, Lu P, Chen KK (2010) Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology 52:528–539
20. Koo BS, Lee SH, Kim JM, Huang S, Kim SH, Rho YS et al (2014) Oct4 is a critical regulator of stemness in head and neck squamous carcinoma cells. Oncogene.doi: 1038/onc.2014.174
21. Marques DS, Sandrini JZ, Boyle RT, Marins LF, Trindade GS (2010) Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines. Leuk Res 34:757–762
22. Lozzio CB, Lozzio BB (1975) Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45(3):321–334
23. Rumjanek VM, Lucena M, Campos MM, Marques-silva VM, Maia RC (1994) Multidrug resistance in leukemias: the problem and some approaches to its circumvention. J Braz Assoc Adv Sci 46(1/2):63–69
24. Rumjanek VM, Trindade GS, Wagner-Souza K, Meletti-de-Oliveira MC, Marques-Santos LF, Maia RC et al (2001) Multidrug resistance in tumour cells: characterisation of the multidrug resistant cell line K562-Lucena 1. An Acad Bras Ciênc 73(1):57–69
25. Maia RC, Silva EAC, Harab RC, Lucena M, Pires V, Rumjanek VM (2001) Sensitivity of vincristine-sensitive K562 and vincristine-resistant K562-Lucena 1 cells to anthracyclines and reversal of multidrug resistance. Braz J Med Biol Res 29(4):467–472
26. Maia RC, Wagner K, Cabral RH, Rumjanek VM (1996) Heparin reverses Rhodamine 123 extrusion by multidrug resistant cells. Cancer Lett 106:101–108
27. Orind M, Wagner-Souza K, Maia RC, Rumjanek VM (1997) Modulation of P-glycoprotein on tumour cells. In: Sotelo JR & Benech JC (Ed.): Calcium and cellular metabolism: transport and regulation. Plenum Press: Newyork NY, 72(1), pp 117–124
28. Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucl Acid Res 30:1–10
29. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (San Diego, Calif.) 25(4): 402–408
30. Quandt K, Frech K, Karas H, Wingender E, Werner T (1995) MatInd and matInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucl Acid Res 23:4878–4884
31. Tamura K, Nei M (1993) Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol Biol Evol 10(3):512–526
32. Peri S, Navarro JD, Amanchy R, Kristiansen TZ, Jonnalagadda CK, Surendranath V et al (2003) Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res 13:2363–2371
33. Guo Y, Costa R, Ramsey H, Starnes T, Vance G, Robertson K et al (2002) The embryonic stem cell transcription factors Oct-4 and FoxD3 interact to regulate endodermal-specific promoter expression. Proc Natl Acad Sci USA 99:3663–3667
34. Kim J, Chu J, Shen X, Wang J, Orkin SH (2008) An extended transcriptional network for pluripotency of embryonic stem cells. Cell 132:1049–1061
35. Scotto KW (2003) Transcriptional regulation of ABC drug transporters. Oncogene 22:7496–7511
36. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S et al (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917–1920
37. Brumbaugh J, Hou Z, Russell JD, Howden SE, Yu P, Ledvina AR et al (2012) Phosphorylation regulates human OCT4. Proc Natl Acad Sci 109(19):7162–7168
38. Brehm A, Ohbo K, Schöler H (1997) The carboxy-terminal transactivation domain of Oct-4 acquires cell specificity through the POU domain. Mol Cell Biol 17:154–162